Antibody therapy for high-risk Covid-19 patients

USA – The World Health Organization (WHO) has added the Regeneron antibody drug cocktail (casirivimab and imdevimab) to its list of COVID-19 treatments, urging the manufacturer to lower its price and ensure equal access to the lifesaving treatment worldwide. WHO added that Regeneron, the patent holder should also share technology to allow for the manufacturing of biosimilar versions of the monoclonal antibody therapy. The guidelines published in the British Medical Journal (BMJ), strongly recommend that patients at high risk of hospitalization or with severe disease should be given a combination…

Read More